Laurus Labs in pact with The Global Fund

Published - March 26, 2019 10:17 pm IST - HYDERABAD

Drug maker Laurus Labs has entered into a strategic partnership agreement with The Global Fund, a three-and-a-half-year pact that will fetch the company volume commitments from the fund for treatment of HIV/AIDS.

Announcing the agreement, the company on Tuesday said it had also received and executed an order for the fund that involved supplies to the high disease-burden countries in the sub Saharan African region.

It was the first order for the company’s fixed dose combination drug Tenofovir/Lamivudine/Dolutegravir 300/300/50mg (TLD).

A preferred first-line regimen for the treatment of people living with HIV, the company’s product had received a tentative approval from the US Food and Drug Administration last month. Laurus Labs shares gained 3.77%, or ₹14.10, to close at ₹388.60 apiece on Tuesday.

Founder and CEO Satyanarayana Chava said “we thank The Global Fund team for placing its trust for a new entrant like us in ARV – FDF (Anti-Retroviral – Finished Dosage Forms) space. For Laurus Labs it is a very significant development which has ventured into the FDFs couple of years ago.”

The Global Fund, founded in 2002, is a partnership involving the governments, civil society, private sector as well as people affected by AIDS, tuberculosis and malaria. It raises and invests nearly $4 billion a year to support programmes run by local experts in countries and communities most in need, according to a release from Laurus Labs.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.